Reimagining the Treatment of Pelvic Health Disorders

Reimagining the
Treatment of Pelvic
Health Disorders

EBT was founded on the discovery of the Saphenous nerve’s role in modulating pelvic health function, enabling entirely new approaches to treating a wide variety of indications, beginning with overactive bladder.

EBT was founded on the discovery of the Saphenous nerve’s role in modulating pelvic health function, enabling entirely new approaches to treating a wide variety of indications, beginning with overactive bladder.

Spun out of the University of Toronto, EBT Medical is a venture-backed, clinical-stage company developing paradigm-shifting neuromodulation technologies focused on treating pelvic health disorders via the Saphenous nerve.

EBT’s vision is to completely reimagine how pelvic health disorders are treated– elevating neuromodulation from a last-line alternative to the forefront of every patient’s journey.

A drug-free

Noninvasive Solution
for Overactive Bladder

Noninvasive Solution for Overactive Bladder

Our Team

EBT Medical is backed by world-class investors including SV Health Investors and Genesys Capital. Our Medical Advisory Board includes leading experts in the pelvic health space, and our impressive, diverse management team has decades of experience in Class II & III medical devices, with proven track records in neuromodulation and pelvic health.

Keith R Carlton

Chief Executive Officer

Scott MacDiarmid, MD

Chair, Medical Advisory Board

Paul Yoo, PhD

Co-Founder, President, &
Chief Scientific Officer

0

Our first product, NiNA*, is a novel non-invasive neurostimulator and disease-management ecosystem for patients with overactive bladder, centered on stimulation of the Saphenous nerve. With NiNA, EBT aims to reach tens of millions of sufferers globally who are searching for an effective alternative to medications and surgery. Clinical validation of saphenous nerve stimulation will allow EBT to disrupt the existing market for drugs and devices, while driving dramatic market expansion, addressing a highly undertreated population. Our planned at-home therapy and associated digital ecosystem is designed to achieve relief on-par with invasive therapies, except with virtually no side-effects– restoring patients’ dignity and independence.